Abstract
No translate
No translate
No translate
No translate
Nguyễn Văn Triệu
References
1.
1. World Health Organization (2013) A global brief on hypertension -World Health Day 2013.
2.
2. Lewington S, Clarke R, Qizilbash N, et al (2002) Age-specific relevance of usual blood pressure to vascular mortality: a metaanalysis of individual data for one million adults in 61 prospective studies. Lancet 360:1903–1913.
3.
3. Mills KT, Bundy JD, Kelly TN et al (2016) Global disparities of hypertension prevalence and control- global disparities of hypertension prevalence and control a systematic analysis of population-based studies from 90 countries. Circulation 134:441–450.
4.
4. Lu J, Lu Y, Wang X, et al (2017). Prevalence, awareness, treatment, and control of hypertension in China: data from 1•7 million adults in a population-based screening study (China PEACE Million Persons Project). Lancet. Doi: http://dx.doi.org/10.1016/ S0140-6736(17)32478-9.
5.
5. PT Son, NN Quang, NL Viet, PG Khai, et al (2012). Prevalence, awareness, treatment and control of hypertension in Vietnam - results from a national survey. Journal of Human Hypertensionvolume 26, 268-280.
6.
6. Nguyen QN, Pham ST, Stig Wal, et al (2012). Time trend in blood pressure, body mass index and smoking in Vietnamese population: a meta-analysis from multiple cross-sectional surveys. Plos one 7(8): e42825.
7.
7. Parati G, Stergiou G, O’Brien E et al (2014) European society of hypertension practice guidelines for ambulatory blood pressure monitoring. J Hypertens 32:1359–1366.
8.
8. Kjeldsen SE, Lund-Johansen P, Nilsson PM, Mancia G (2016) Unattended blood pressure measure- ments in the systolic blood pressure intervention trial: Implications for entry and achieved blood pressure values compared with other trials. Hypertension 67:808–812.
9.
9. Banegas JR, Ruilope LM, de la Sierra A et al (2018) Relationship between clinic and ambulatory blood-pressure measurements and mortality. N Engl J Med 378:1509–1520.
10.
10. Whelton PK, Carey RM, Aronow WS, et al (2017). 2017 ACC/AHA, AAPA, ABC/ACPM, AGS/ APhA/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. JACC Vol 71, No 19:e127-248.
11.
11. Kempner W (1948) Treatment of hypertensive vascular disease with rice diet. Am J Med 4:545–577.
12.
12. Center for Disease Control (2010) Centers for disease control and prevention morbidity and mortality weekly report. MMWR. Morb Mortal Wkly Rep 59(24):746–749.
13.
13. Williams B, Mancia G, Spiering W, et al (2018). 2018 ESC/ESH Guidelines for themanagement of arterial hypertension. European Heart Journal. doi:10.1093/eurheartj/ehy339.
14.
14. Sen S (1936) Some observations on decapsulation and denervation of the kidney. Br J Urol 8:319–328
15.
15. Smithwick RH, Thompson JE (1953) Splanchnicectomy for essential hypertension: results in 1,266 cases. J Am Med Assoc 152:1501–1504.
16.
16. Böhm M, Linz D, Ukena C et al (2014) Renal denervation for the treatment of cardiovascular high risk-hypertension or beyond? Circ Res 115:400–409.
17.
17. Vogl A (1950) The discovery of the organic mercurial diuretics. Am Heart J 39:881–883.
18.
18. Day M, Rand M (1963) A hypothesis for the mode of action of alpha-methyldopa in relieving hypertension. J Pharm Pharmacol 15:221–224.
19.
19. Wolf M, Ewen S, Mafoud F, etal (2018). Hypertension: history and development of established and novel treatments. Clinical Research in Cardiology (2018) 107 (Suppl 2):S16–S29.
20.
20. Calhoun D, Jones D, Textor S et al (2008) Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 117:e510–e526.
21.
21. Williams B, Macdonald TM, Morant S et al (2015) Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 386:2059–2068.
22.
22. Bhatt DL, Kandzari DE, O’Neill WW et al (2014) A controlled trial of renal denervation for resistant hypertension. N Engl J Med 370:1393–1401.
23.
23. Azizi M, Sapoval M, Gosse P et al (2015) Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. Lancet 385:1957–1965.
24.
24. Ewen S, Böhm M, Mahfoud F (2017) Long-term follow-up of baroreflex activation therapy in resistant hypertension: Another piece of the puzzle? Hypertension 69:782–784.
25.
25. Lobo MD, Ott C, Sobotka PA et al (2017) Central iliac arteriovenous anastomosis for uncontrolled hypertension: one-year results from the ROX CONTROL HTN Trial. Hypertens (Dallas. Tex 1979) 70:1099–1105.
26.
26. Spiering W, Williams B, Van der Heyden J et al (2017) Endovascular baroreflex amplification for resistant hypertension: a safety and proof-of-principle clinical study. Lancet 390:2655–2661.
Tác giả
Nguyễn Lân Việt: Viện Tim mạch Việt Nam - Bệnh viện Bạch Mai;
Đỗ Doãn Lợi: Viện Tim mạch Việt Nam - Bệnh viện Bạch Mai;
Nguyễn Thị Bạch Yến: Viện Tim mạch Việt Nam - Bệnh viện Bạch Mai;
Văn Đức Hạnh: Viện Tim mạch Việt Nam - Bệnh viện Bạch Mai;
Files
Article Views1586
Document Views1
Downloads9
Section
CHUYÊN ĐỀ
Issue
Số 84+85 , 2019
Category
TĂNG HUYẾT ÁP
Pages
25-32
Copyright Holder
2018 Tạp chí Tim mạch học Việt Nam